Chinese biotech startup adds $315M to the bank after bringing 5 Takeda drugs to its fold
More than two years after arriving on the China biopharma scene with a $322 million deal for five of Takeda’s drugs, Hasten Biopharma has landed $315 million to fuel future acquisitions.
CBC Group, the investment firm that helped put the company together, is once again headlining the round, joined by Abu Dhabi sovereign wealth fund Mubadala in co-leading a lineup of institutional investors.
Hasten is based in Hefei, a five-hour drive to the east from China’s biotech hub in Shanghai, and according to its website, has built a team of more than 700 people since launching in 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.